Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates.
age‐standardized incidence rates
age‐standardized mortality rates
burden and projection
cancer
men
mortality‐to‐incidence ratio
prevalence
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
revised:
20
04
2024
received:
23
12
2023
accepted:
07
06
2024
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
12
8
2024
Statut:
aheadofprint
Résumé
Men exhibit higher prevalence of modifiable risk factors, such as smoking and alcohol consumption, leading to greater cancer incidence and lower survival rates. Comprehensive evidence on global cancer burden among men, including disparities by age group and country, is sparse. To address this, the authors analyzed 30 cancer types among men in 2022, with projections estimated for 2050. The 2022 GLOBOCAN estimates were used to describe cancer statistics for men in 185 countries/territories worldwide. Mortality-to-incidence ratios (MIRs) were calculated by dividing age-standardized mortality rates by incidence rates. In 2022, a high MIR (indicating poor survival) was observed among older men (aged 65 years and older; 61%) for rare cancer types (pancreatic cancer, 91%) and in countries with low a Human Development Index (HDI; 74%). Between 2022 and 2050, cancer cases are projected to increase from 10.3 million to 19 million (≥84%). Deaths are projected to increase from 5.4 million to 10.5 million (≥93%), with a greater than two-fold increase among men aged 65 years and older (≥117%) and for low-HDI and medium-HDI countries/territories (≥160%). Cancer cases and deaths are projected to increase among working-age groups (≥39%) and very-high-HDI countries/territories (≥50%). Substantial disparities in cancer cases and deaths were observed among men in 2022, and these are projected to widen by 2050. Strengthening health infrastructure, enhancing workforce quality and access, fostering national and international collaborations, and promoting universal health coverage are crucial to reducing cancer disparities and ensuring cancer equity among men globally.
Sections du résumé
BACKGROUND
BACKGROUND
Men exhibit higher prevalence of modifiable risk factors, such as smoking and alcohol consumption, leading to greater cancer incidence and lower survival rates. Comprehensive evidence on global cancer burden among men, including disparities by age group and country, is sparse. To address this, the authors analyzed 30 cancer types among men in 2022, with projections estimated for 2050.
METHODS
METHODS
The 2022 GLOBOCAN estimates were used to describe cancer statistics for men in 185 countries/territories worldwide. Mortality-to-incidence ratios (MIRs) were calculated by dividing age-standardized mortality rates by incidence rates.
RESULTS
RESULTS
In 2022, a high MIR (indicating poor survival) was observed among older men (aged 65 years and older; 61%) for rare cancer types (pancreatic cancer, 91%) and in countries with low a Human Development Index (HDI; 74%). Between 2022 and 2050, cancer cases are projected to increase from 10.3 million to 19 million (≥84%). Deaths are projected to increase from 5.4 million to 10.5 million (≥93%), with a greater than two-fold increase among men aged 65 years and older (≥117%) and for low-HDI and medium-HDI countries/territories (≥160%). Cancer cases and deaths are projected to increase among working-age groups (≥39%) and very-high-HDI countries/territories (≥50%).
CONCLUSIONS
CONCLUSIONS
Substantial disparities in cancer cases and deaths were observed among men in 2022, and these are projected to widen by 2050. Strengthening health infrastructure, enhancing workforce quality and access, fostering national and international collaborations, and promoting universal health coverage are crucial to reducing cancer disparities and ensuring cancer equity among men globally.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Global Burden of Disease 2019 Cancer Collaboration; Kocarnik JM, Compton K, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420‐444. doi:10.1001/jamaoncol.2021.6987
Mahase E. Cancer overtakes CVD to become leading cause of death in high income countries. BMJ. 2019;366:l5368. doi:10.1136/bmj.l5368
Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029‐3030. doi:10.1002/cncr.33587
Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465‐472. doi:10.1001/jamaoncol.2022.7826
Lang MJ, David V, Giese‐Davis J. The age conundrum: a scoping review of younger age or adolescent and young adult as a risk factor for clinical distress, depression, or anxiety in cancer. J Adolesc Young Adult Oncol. 2015;4(4):157‐173. doi:10.1089/jayao.2015.0005
Wang Y, Feng W. Cancer‐related psychosocial challenges. Gen Psychiatr. 2022;35(5):e100871. doi:10.1136/gpsych‐2022‐100871
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249. doi:10.3322/caac.21660
Lui PSC, Singh K, Nguyen T, et al. Determinants of cancer screenings participation in Queensland: a scoping review. J Prim Health Care. 2023;16(1):70‐77. doi:10.1071/hc23012
Dai X, Gakidou E, Lopez AD. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control. 2022;31(2):129‐137. doi:10.1136/tobaccocontrol‐2021‐056535
Carey RN, Hutchings SJ, Rushton L, et al. The future excess fraction of occupational cancer among those exposed to carcinogens at work in Australia in 2012. Cancer Epidemiol. 2017;47:1‐6. doi:10.1016/j.canep.2016.12.009
Huang J, Ssentongo P, Sharma R. Editorial: Cancer burden, prevention and treatment in developing countries. Front Public Health. 2022;10:1124473. doi:10.3389/fpubh.2022.1124473
Gbdayac C, Force LM, Xu R, et al. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol. 2022;23(1):27‐52. doi:10.1016/s1470‐2045(21)00581‐7
Dharmarajan KV, Presley CJ, Wyld L. Care disparities across the health care continuum for older adults: lessons from multidisciplinary perspectives. Am Soc Clin Oncol Educ Book. 2021;41:e215‐e224. doi:10.1200/edbk_319841
Van Herck Y, Feyaerts A, Alibhai S, et al. Is cancer biology different in older patients? Lancet Healthy Longev. 2021;2(10):e663‐e677. doi:10.1016/s2666‐7568(21)00179‐3
Asadzadeh Vostakolaei F, Karim‐Kos HE, Janssen‐Heijnen ML, Visser O, Verbeek AL, Kiemeney LA. The validity of the mortality to incidence ratio as a proxy for site‐specific cancer survival. Eur J Public Health. 2011;21(5):573‐577. doi:10.1093/eurpub/ckq120
Eberth JM, Zahnd WE, Adams SA, Friedman DB, Wheeler SB, Hebert JR. Mortality‐to‐incidence ratios by US congressional district: implications for epidemiologic, dissemination and implementation research, and public health policy. Prev Med. 2019;129S:105849. doi:10.1016/j.ypmed.2019.105849
Yang TW, Wang CC, Hung WC, Liu YH, Sung WW, Tsai MC. Improvement in the mortality‐to‐incidence ratios for gastric cancer in developed countries with high health expenditures. Front Public Health. 2021;9:713895. doi:10.3389/fpubh.2021.713895
Batouli A, Jahanshahi P, Gross CP, Makarov DV, Yu JB. The global cancer divide: relationships between national healthcare resources and cancer outcomes in high‐income vs. middle‐ and low‐income countries. J Epidemiol Glob Health. 2014;4(2):115‐124. doi:10.1016/j.jegh.2013.10.004
Choi E, Lee S, Nhung BC, et al. Cancer mortality‐to‐incidence ratio as an indicator of cancer management outcomes in Organization for Economic Cooperation and Development countries. Epidemiol Health. 2017;39:e2017006. doi:10.4178/epih.e2017006
Li J. Digestive cancer incidence and mortality among young adults worldwide in 2020: a population‐based study. World J Gastrointest Oncol. 2022;14(1):278‐294. doi:10.4251/wjgo.v14.i1.278
United States Cancer Statistics. Mortality Incidence Rate Ratios 1999–2011, WONDER Online Database. US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
Cancer Australia. National Cancer Control Indicators. Mortality‐to‐incidence ratio. Cancer Australia; 2022. Accessed September 2, 2023. https://ncci.canceraustralia.gov.au/outcomes/mortality‐incidence‐ratio/mortality‐incidence‐ratio
Sharma R. Mapping of global, regional and national incidence, mortality and mortality‐to‐incidence ratio of lung cancer in 2020 and 2050. Int J Clin Oncol. 2022;27(4):665‐675. doi:10.1007/s10147‐021‐02108‐2
Sung WW, Wang SC, Hsieh TY, et al. Favorable mortality‐to‐incidence ratios of kidney cancer are associated with advanced health care systems. BMC Cancer. 2018;18(1):792. doi:10.1186/s12885‐018‐4698‐6
Amini M, Looha MA, Zarean E, Pourhoseingholi MA. Global pattern of trends in incidence, mortality, and mortality‐to‐incidence ratio rates related to liver cancer, 1990–2019: a longitudinal analysis based on the global burden of disease study. BMC Public Health. 2022;22(1):604. doi:10.1186/s12889‐022‐12867‐w
Wang SC, Sung WW, Kao YL, et al. The gender difference and mortality‐to‐incidence ratio relate to health care disparities in bladder cancer: national estimates from 33 countries. Sci Rep. 2017;7(1):4360. doi:10.1038/s41598‐017‐04083‐z
Pilleron S, Soto‐Perez‐de‐Celis E, Vignat J, et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050. Int J Cancer. 2021;148(3):601‐608. doi:10.1002/ijc.33232
United Nations Development Program. Human Development Report 2021–22. Uncertain Times, Unsettled Lives: Shaping our Future in a Transforming World. United Nations; 2022. Accessed March 10, 2024. https://www.undp.org/egypt/publications/human‐development‐report‐2021‐22‐uncertain‐times‐unsettled‐lives‐shaping‐our‐future‐transforming‐world
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778‐789. doi:10.1002/ijc.33588
World Health Organization (WHO). WHO Civil Registration and Vital Statistics Strategic Implementation Plan 2021–2025. WHO; 2021.
Sedeta E, Sung H, Laversanne M, Bray F, Jemal A. Recent mortality patterns and time trends for the major cancers in 47 countries worldwide. Cancer Epidemiol Biomarkers Prev. 2023;32(7):894‐905. doi:10.1158/1055‐9965.epi‐22‐1133
World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems, 5th ed. 10th revision. World Health Organization; 2016. Accessed June 27, 2024. https://apps.who.int/iris/handle/10665/246208
United Nations. Dependency Ratio. Accessed September 2, 2023. https://www.un.org/esa/sustdev/natlinfo/indicators/methodology_sheets/demographics/dependency_ratio.pdf
United Nations Development Program. Human Development Reports. Human Development Index (HDI). Accessed December 23, 2023. https://hdr.undp.org/data‐center/human‐development‐index#/indicies/HDI
International Agency for Research on Cancer (IARC). Data and Methods. IARC; 2023. Accessed April 6, 2024. https://gco.iarc.fr/today/en/data‐sources‐methods
Doll R, Payne P, Waterhouse J, eds. Cancer Incidence in Five Continents. A Technical Report. Springer; 1966.
Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today (version 1.1). International Agency for Research on Cancer; 2024. Accessed April 6, 2024. https://gco.iarc.who.int/today
Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15‐23. doi:10.1016/j.breast.2022.08.010
Ferlay J, Laversanne M, Ervik M, et al. Global Cancer Observatory: Cancer Tomorrow (version 1.1). International Agency for Research on Cancer; 2024. Accessed April 6, 2024. https://gco.iarc.fr/tomorrow
Bray F, Moller B. Predicting the future burden of cancer. Nat Rev Cancer. 2006;6(1):63‐74. doi:10.1038/nrc1781
Bizuayehu HM, Dadi AF, Hassen TA, et al. Global burden of 34 cancers among women in 2020 and projections to 2040: population‐based data from 185 countries/territories. Int J Cancer. 2023;154(8):1377‐1393. doi:10.1002/ijc.34809
Gallicchio L, Daee DL, Rotunno M, et al. Epidemiologic research of rare cancers: trends, resources, and challenges. Cancer Epidemiol Biomarkers Prev. 2021;30(7):1305‐1311. doi:10.1158/1055‐9965.epi‐20‐1796
Dos‐Santos‐Silva I, Gupta S, Orem J, Shulman LN. Global disparities in access to cancer care. Commun Med (Lond). 2022;2(1):31. doi:10.1038/s43856‐022‐00097‐5
Prager GW, Braga S, Bystricky B, et al. Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open. 2018;3(2):e000285. doi:10.1136/esmoopen‐2017‐000285
Romero Y, Trapani D, Johnson S, et al. National cancer control plans: a global analysis. Lancet Oncol. 2018;19(10):e546‐e555. doi:10.1016/s1470‐2045(18)30681‐8
United Nations Department of Economic and Social Affairs. Sustainable Development Goal 3: ensure healthy lives and promote well‐being for all at all ages. United Nations; 2023. Accessed June 27, 2024. https://sdgs.un.org/goals/goal3
Anderson K, Diaz A, Parikh DR, Garvey G. Accessibility of cancer treatment services for Indigenous Australians in the Northern Territory: perspectives of patients and care providers. BMC Health Serv Res. 2021;21(1):95. doi:10.1186/s12913‐021‐06066‐3
Nyandekwe M, Nzayirambaho M, Kakoma JB. Universal health insurance in Rwanda: major challenges and solutions for financial sustainability case study of Rwanda community‐based health insurance part I. Pan Afr Med J. 2020;37:55. doi:10.11604/pamj.2020.37.55.20376
McDonald R, ed. Understanding Rare and Less Common Cancers. A guide for people with cancer, their families and friends. Cancer Council Australia; 2021. Accessed February 20, 2023. https://www.cancervic.org.au/downloads/resources/booklets/Understanding‐Rare‐and‐Less‐Common‐Cancers.pdf
McIntosh SA, Alam F, Adams L, et al. Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments. Lancet Oncol. 2023;24(6):636‐645. doi:10.1016/s1470‐2045(23)00182‐1
Kamaraju S, Drope J, Sankaranarayanan R, Shastri S. Cancer prevention in low‐resource countries: an overview of the opportunity. Am Soc Clin Oncol Educ Book. 2020;40:72‐83. doi:10.1200/edbk_280625
International Agency for Research on Cancer (IARC). Cancer Registries: A Worldwide Endeavour. IARC; 2022. Accessed December 21, 2022. https://www.iarc.who.int/wp‐content/uploads/2018/07/IARC_Ch4.1.3_web.pdf
Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population‐based study (CONCORD). Lancet Oncol. 2008;9(8):730‐756. doi:10.1016/s1470‐2045(08)70179‐7
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD‐3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population‐based registries in 71 countries. Lancet. 2018;391(10125):1023‐1075. doi:10.1016/s0140‐6736(17)33326‐3